Zhang, Q. and Xu, B. and Zhang, Q. and Sun, T. and Li, W. and Teng, Y. and Hu, X. and Bondarenko, I. and Adamchuk, H. and Zhang, L. and Trukhin, D. and Wang, S. and Zheng, H. and Tong, Z. and Zhang, X. and Liu, E. and Jiang, W. and Liu, S. and Luk, A. (2018) Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab. Annals of Oncology, Vol.29 (Supp.9). ix16. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
![[img]](https://repo.dma.dp.ua/style/images/fileicons/text.png) |
Text
mdy428.005.pdf Download (83kB) |
Official URL: https://www.journals.elsevier.com/annals-of-oncolo...
Abstract
HLX02 is being developed to address the current global need for high quality yet affordable trastuzumab biosimilar (trastuzumab) for patients with breast cancer.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Breast cancer, metastatic |
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 01 Mar 2021 14:25 |
| Last Modified: | 01 Mar 2021 14:26 |
| URI: | http://repo.dma.dp.ua/id/eprint/6282 |
Actions (login required)
 |
View Item |
